Improvement of the affinity and druglike properties of this Cdc42-binding sequence could therefore generate a specific, competitive inhibitor for Cdc42 effector signaling with potential as a clinically useful inhibitor for Ras-driven cancers. This evidence concerns the gene CDC42 and cancer.